



Figure 1

across hematologic malignancies and is a well-tolerated chemotherapy with a limited side effect profile. The modest dosing in combination with corticosteroids allows initial disease control and provides the ability to start definitive therapy in a timely manner. Additionally, we feel that pCy should be considered when designing clinical trials in an effort to promote enrollment of the "real-world" patient.

Disclosures Kota: *Incyte:* Research Funding; *Pfizer:* Honoraria; *Kite:* Honoraria; *Novartis:* Honoraria. **Cortes:** *Takeda:* Consultancy, Honoraria; *Gilead:* Consultancy; *Forma Therapeutic:* Consultancy; *Abbvie:* Consultancy, Research Funding; *Biopath Holdings:* Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Pfizer:* Consultancy, Research Funding; *Novartis:* Consultancy, Research Funding. **Kerukous:** *BMS:* Membership on an entity's Board of Directors or advisory committees; *Janssen:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

<https://doi.org/10.1182/blood-2023-190805>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/6316/2196619/blood-2913-main.pdf by guest on 11 June 2024